| Literature DB >> 25275049 |
Leen Vanacker1, Dominiek Smeets2, Anne Hoorens3, Erik Teugels1, Roberto Algaba4, Marie Françoise Dehou4, Ann De Becker5, Diether Lambrechts2, Jacques De Greve6.
Abstract
BACKGROUND/AIM: We report a case of a mixed adenoneuroendocrine carcinoma developed in a colorectal adenocarcinoma with lymph node and liver metastases exclusively emanating from the neuroendocrine carcinoma component. The patient underwent right hemicolectomy and postoperatively received chemotherapy with cisplatin and etoposide and subsequent high-dose induction chemotherapy, followed by autologous stem cell transplantation. Following this treatment, there was a complete remission. Currently, thirty months after treatment, the patient is in unmaintained complete remission. Comparative exome sequencing of germline DNA and DNA from the two separate malignant components revealed six somatic changes in cancer consensus genes. Both components shared somatic mutations in Adenomatous polyposis coli (APC), Kirsten rat sarcoma viral oncogene homolog (KRAS), B-cell CLL/lymphoma 9 (BCL9) and Forkhead Box P1 (FOXP1) genes. Mutation in SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 (SMARCA4) was only found in the neuroendocrine carcinoma component. The finding of several identical somatic mutations in both components supports a clonal relationship between the neuroendocrine carcinoma and the adenocarcinoma. We suggest that a mutation in SMARCA4 could be responsible for the transformation of the adenocarcinoma component into the neuroendocrine phenotype. CopyrightEntities:
Keywords: MANEC; Mixed adenoneuroendocrine carcinoma; SMARCA4; autologous stem cell transplantation; colorectal adenocarcinoma; exome sequencing; high-dose chemotherapy; long-term survival
Mesh:
Year: 2014 PMID: 25275049
Source DB: PubMed Journal: Anticancer Res ISSN: 0250-7005 Impact factor: 2.480